Navigation Links
General tumor marker test now offered by GenWay clinical laboratory
Date:8/21/2009

(San Diego, CA) August 21, 2009 GenWay Clinical Laboratory, a US-based diagnostic company with CLIA certification, has validated a general tumor marker test in their laboratory and now offers this testing service. This is an ELISA-based assay which simply requires a small blood sample from the patient in order to quantify the amount of the tumor marker in their serum. This unique and proprietary test formula detects and quantifies specific biomarkers, tumor fibrin and fibrinogen degradation products (tFFDP), which are by-products of cancer cells. Elevated tFFDP levels have been associated with at least 14 different cancer types including lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, brain and pancreatic cancer making it one of the most versatile cancer biomarkers available. GenWay is continuing to evaluate the use of this test in other applications. This general tumor marker test can identify elevated levels of tFFDP in a patient which could potentially correspond to the presence of a malignant tumor.


'/>"/>

Contact: Jill Dombrauckas, Ph.D.
jdom@genwaybio.com
GenWay Biotech
Source:Eurekalert

Page: 1

Related biology news :

1. American Society for Microbiology to host 109th general meeting in Philadelphia
2. Journal of General Physiology explores mysteries of TRP channels in latest Perspectives series
3. Mass. Generals Warren Triennial Prize honors discoverers of microRNAs
4. March of Dimes announces Prematurity Campaign expansion at Surgeon Generals conference
5. Mass. General study shows how exercise changes structure and function of heart
6. American Society for Microbiology 108th General Meeting
7. Remarks Prepared for Delivery By Attorney General Michael B. Mukasey At the Ministerial Press Conference
8. In nature -- and maybe the corner office -- scientists find that generalists can thrive
9. Generalist bacteria discovered in coastal waters may be more flexible than known before
10. Society for General Microbiology 161st Meeting, University of Edinburgh
11. Tumor suppressor pulls double shift as reprogramming watchdog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
Breaking Biology Technology: